MAGE-A4ᶜ¹º³²T for Multi-Tumor
Public ClinicalTrials.gov record NCT03132922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Study identification
- NCT ID
- NCT03132922
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- USWM CT, LLC
- Industry
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Interventions
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation Radiation
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells Genetic
Radiation · Genetic
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 14, 2017
- Primary completion
- Dec 26, 2022
- Completion
- Aug 31, 2032
- Last update posted
- May 6, 2026
2017 – 2032
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Miami | Miami | Florida | 33136 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Washington University | St Louis | Missouri | 63112 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Duke University Medical Center, Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Tennessee Oncology - Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03132922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2026 · Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03132922 live on ClinicalTrials.gov.